One limitation of in vivo gene therapy is:
Direct in vivo administration viral vectors faces major limitation reduced control which cells internalize vector genome achieve therapeutic expression compared ex vivo selection. Systemic IV infusion distributes AAV particles according cardiac output vascular permeability liver sinusoidal fenestrations 100 nm capturing ~90 percent dose via heparan sulfate proteoglycan uptake hepatocytes Kupffer macrophages while target skeletal myofibers CNS neurons behind blood-brain barrier differentiated airway epithelia receive subtherapeutic copy numbers below threshold efficacy. No selection feasible af
Ref: Molecular Therapy In Vivo Targeting Limitations 2021; FDA Guidance In Vivo Gene Therapy Low Control Challenges; Lodish Gene Delivery Biodistribution Barriers Chap 9.